Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population

doi:10.3748/wjg.v20.i47.17932

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 47

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12693)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

878

WORD

321

HTML

8268

Tables (1-4)

324

Sum=9791

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1245

Download

1657

Sum=2902

Dec 21, 2014 (publication date) through Feb 12, 2025

Times Cited of This Article

Times Cited (168)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Evidence-Based Medicine

World J Gastroenterol. Dec 21, 2014; 20(47): 17932-17940
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.17932

Table 1 Baseline demographic characteristics of non-alcoholic fatty liver disease patients and controls

	Lean-NAFLD (n = 731)		Overweight-obese-NAFLD (n = 1048)		P value
	Controls	NAFLD	Controls	NAFLD	P value
Participants, n (%)	597 (81.67)	134 (18.33)	284 (27.10)	764 (72.90)
Age (yr)	43.19 ± 11.59	48.17 ± 10.5^a	46.72 ± 11.15^b	46.92 ± 11.19	< 0.01
Male (%)	28.48	54.48	51.41	72.25	< 0.01
Education (%)
Never	0.66	1.92	0.90	0.87	0.30
Primary	0.66	0.00	2.26	1.56
Junior	4.20	2.88	6.33	3.65
Senior	15.27	11.54	19.46	18.92
College	63.50	66.35	58.37	61.98
Postgraduate	15.71	17.31	12.67	13.02
BMI (kg/m²)	21.37 ± 1.71	22.74 ± 1.13^a	25.98 ± 1.66^b	27.57 ± 2.63^a^c	< 0.01
Body weight (kg)	57.64 ± 7.14	64.09 ± 7.31^a	71.32 ± 9.49^b	78.81 ± 11.64^a^c	< 0.01
Body fat (%)	24.83 ± 5.40	26.17 ± 4.96^a	29.61 ± 4.73^b	30.05 ± 4.49^c	< 0.01
Body fat mass (kg)	14.26 ± 3.37	16.59 ± 2.68^a	20.91 ± 3.34^b	23.59 ± 4.61^a^c	< 0.01
WC (cm)	75.50 ± 7.06	82.42 ± 6.29^a	87.06 ± 7.16^b	93.45 ± 8.70^c	< 0.01
VAI	1.52 ± 1.99	2.04 ± 2.21^a	1.85 ± 2.32^b	2.08 ± 1.50	< 0.01
SBP (mmHg)	119.48 ± 15.45	126.46 ± 16.24^a	129.37 ± 19.86^b	132.20 ± 17.29^c	< 0.01
DBP (mmHg)	74.04 ± 10.04	80.05 ± 11.74^a	79.33 ± 12.17^b	82.84 ± 10.57^a^c	< 0.01
Physical activity (%)
None	83.92	89.52	80.27	85.10	0.45
Moderate	14.98	10.48	18.39	13.86
Vigorous	1.10	0.00	1.35	1.04
Drinking (%)	23.82	36.89	39.25	49.02	< 0.01
Smoking (%)
Never	86.09	82.52	81.45	68.34	< 0.01
≤ 1 cigarettes/d	1.10	0.97	1.36	2.25
≤ 10 cigarettes/d	5.08	3.88	5.43	7.96
≤ 20 cigarettes/d	5.74	8.74	7.24	14.01
> 20 cigarettes/d	1.99	3.88	4.52	7.44
Diabetes (%)	4.58	15.67	9.54	16.49	< 0.01
Hypertension (%)	12.23	34.71	32.08	43.67	< 0.01
Hyperlipidemia (%)	34.20	49.25	47.69	59.47	< 0.01
MS (%)	3.06	14.53	26.47	46.64	< 0.01
Central obesity (%)	14.96	29.41	69.55	84.64	< 0.01
Obesity (%)	0.00	0.00	11.97	37.70	< 0.01

^aP < 0.05 vs control in same weight group;

^bP < 0.05 vs Lean-control group,

^cP < 0.05 vs Lean-NAFLD group. NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index; WC: Waist circumstance; VAI: Visceral adiposity index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MS: Metabolic syndrome.

Table 2 Clinical biochemical characteristics of non-alcoholic fatty liver disease and controls

	Lean-NAFLD		Overweight-obese-NAFLD		P value
	Controls	NAFLD	Controls	NAFLD	P value
FBG (mmol/L)	5.30 ± 1.36	5.91 ± 1.85^a	5.52 ± 1.31^b	5.76 ± 1.42^a	< 0.01
Fasting insulin (IU/mL)	6.42 ± 3.76	8.27 ± 3.93^a	7.28 ± 4.33	10.84 ± 5.28^a^c	< 0.01
HOMA-IR	1.55 ± 0.97	2.16 ± 1.42^a	1.87 ± 1.35^b	2.73 ± 1.53^a^c	< 0.01
TC (mmol/L)	4.86 ± 0.93	5.20 ± 1.01^a	5.00 ± 0.90^b	5.10 ± 0.92	< 0.01
TG (mmol/L)	1.18 ± 1.13	1.71 ± 1.23^a	1.40 ± 1.01^b	1.83 ± 1.19^a	< 0.01
HDL-C (mmol/L)	1.58 ± 0.35	1.45 ± 0.30^a	1.44 ± 0.30^b	1.35 ± 0.27^a^c	< 0.01
LDL-C (mmol/L)	2.90 ± 0.79	3.12 ± 0.78^a	3.09 ± 0.77^b	3.13 ± 0.78	< 0.01
ALT (U/L)	18.32 ± 13.85	21.61 ± 11.92^a	21.10 ± 16.13^b	27.23 ± 18.25^a^c	< 0.01
AST (U/L)	19.27 ± 6.85	21.07 ± 9.26^a	20.23 ± 11.10	22.37 ± 9.87^a	< 0.01
ALP (U/L)	64.34 ± 18.16	71.96 ± 20.49^a	66.94 ± 21.26	70.00 ± 18.47^a	< 0.01
GGT (U/L)	26.11 ± 27.99	35.76 ± 34.92^a	33.42 ± 33.95^b	47.26 ± 48.44^a^c	< 0.01
UA (μmol/L)	280.04 ± 82.31	303.30 ± 86.72^a	307.59 ± 85.54^b	340.60 ± 92.68^a^c	< 0.01
BUN (mmol/L)	5.00 ± 1.24	5.15 ± 1.25	5.16 ± 1.19	5.14 ± 1.24	0.15
CRE (μmol/L)	69.26 ± 14.37	70.34 ± 13.84	71.72 ± 14.18^b	74.53 ± 14.48^c	< 0.01

^aP < 0.05 vs control in same weight group;

^bP < 0.05 vs Lean-control group;

^cP < 0.05 vs Lean-NAFLD group. NAFLD: Non-alcoholic fatty liver disease; FBG: Fasting blood glucose; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: γ-glutamyl transferase; UA: Serum uric acid; BUN: Blood urea nitrogen; CRE: Serum creatinine.

Table 3 Hematological comparison between non-alcoholic fatty liver disease and controls among four groups

	Lean-NAFLD		Overweight-obese-NAFLD		P value
	Controls	NAFLD	Controls	NAFLD	P value
WBC (10⁹/L)	5.73 ± 1.46	6.40 ± 1.44^a	6.25 ± 1.58^b	6.72 ± 1.66^a^c	< 0.01
NEUT (10⁹/L)	3.28 ± 1.12	3.70 ± 1.04^a	3.62 ± 1.19^b	3.88 ± 1.25^a^c	< 0.01
LYMPH (10⁹/L)	1.96 ± 0.52	2.14 ± 0.56^a	2.10 ± 0.57^b	2.26 ± 0.60^a^c	< 0.01
MONO (10⁹/L)	0.36 ± 0.14	0.39 ± 0.13^a	0.39 ± 0.16^b	0.42 ± 0.15^a	< 0.01
EO (10⁹/L)	0.09 ± 0.09	0.13 ± 0.14^a	0.11 ± 0.10	0.14 ± 0.13^a	< 0.01
BASO (10⁹/L)	0.01 ± 0.04	0.01 ± 0.03	0.01 ± 0.03	0.02 ± 0.03	0.22
RBC (10¹²/L)	4.50 ± 0.41	4.76 ± 0.42^a	4.72 ± 0.48^b	4.96 ± 0.44^a^c	< 0.01
HGB (g/L)	136.13 ± 15.24	145.87 ± 16.44^a	143.30 ± 17.05^b	152.19 ± 14.22^a^c	< 0.01
HCT (%)	41.36 ± 4.11	44.09 ± 4.41^a	43.40 ± 4.55^b	45.68 ± 3.90^a^c	< 0.01

^aP < 0.05 vs control in same weight group;

^bP < 0.05 vs Lean-control group;

^cP < 0.05 vs Lean-NAFLD group. NAFLD: Non-alcoholic fatty liver disease; WBC: White blood cell count; NEUT: Neutrophils count; LYMPH: Lymphocytes count; MONO: Monocytes count; EO: Eosinophils count; BASO: Basophils count; RBC: Red blood cell count; HGB: Hemoglobin; HCT: Hematocrit value.

Table 4 Odds ratios of non-alcoholic fatty liver disease compared with controls

	¹OR (95%CI)	²OR (95%CI)
All NAFLD vs all controls
Hyperlipidemia	2.19 (1.81-2.65)	1.37 (1.04-1.80)
Hypertension	2.98 (2.37-3.74)	1.49 (1.10-2.03)
Diabetes	2.97 (2.14-4.11)	1.68 (1.08-2.62)
MS	6.29 (4.78-8.28)	2.34 (1.65-3.31)
Central obesity	6.56 (5.16-8.33)	1.97 (1.38-2.80)
Lean-NAFLD vs lean controls
Hyperlipidemia	1.87 (1.28-2.73)	1.29 (0.80-2.09)
Hypertension	3.26 (2.08-5.10)	1.72 (1.00-2.96)
Diabetes	3.87 (2.11-7.08)	2.47 (1.14-5.35)
MS	5.38 (2.66-10.89)	3.19 (1.38-7.35)
Central obesity	2.37 (1.44-3.90)	2.17 (1.17-4.05)
Overweight-obese NAFLD vs overweight-obese controls
Hyperlipidemia	1.61 (1.22-2.12)	1.36 (0.96-1.91)
Hypertension	1.64 (1.20-2.24)	1.33 (0.92-1.93)
Diabetes	1.87 (1.21-2.91)	1.34 (0.80-2.27)
MS	2.43 (1.75-3.38)	1.89 (1.29-2.77)

¹OR: Crude OR; ²OR: Adjusted by age, sex, body mass index, smoking, alcohol consumption and physical activities. NAFLD: Non-alcoholic fatty liver disease; OR: Odds ratio; CI: Confidence interval; MS: Metabolic syndrome.

Citation: Feng RN, Du SS, Wang C, Li YC, Liu LY, Guo FC, Sun CH. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol 2014; 20(47): 17932-17940
URL: https://www.wjgnet.com/1007-9327/full/v20/i47/17932.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i47.17932